Clinical Trial: HDL-C in Cardiac Syndrome X

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: HDL-Cholesterol is Inversely Related With Inflammation in Cardiac Syndrome X

Brief Summary:

High density lipoprotein cholesterol (HDL-C) is in the centrum of the process of reverse cholesterol transport from peripheral cells to the liver[10]. HDL-C promotes endothelial generation of nitric oxide (NO) and improves endothelial function and arterial vasoreactivity[11]. In several studies, lower HDL-C level was reported to be associated with increased coronary artery disease (CAD) risk[12-14]. HDL-C also has anti- inflammatory and anti-oxidant activities[15,16]. Concerning anti-inflammatory activity, HDL-C inhibits the activation of monocytes/macrophages and neutrophils[17,18] and inhibits the expression of endothelial adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and E-selectin[15].

In this study we aimed to investigate the relation of HDL-C level with systemic inflammatory markers in patients with cardiac syndrome X (CSX).

Detailed Summary:
Sponsor: Bursa Yüksek İhtisas Education and Research Hospital

Current Primary Outcome:

• HDL-Cholesterol [ Time Frame: 6 MONTHS ]
  HDL-Cholesterol <40 mg/dL(male) / < 50mg/dL(female) ==> low HDL-C
• Cardiac Syndrome X [ Time Frame: 6 months ]
  Patients who have typical anginal chest pain+ischaemic findings at exercise stress test/myocardial scintigraphy + normal epicardial coronaries at coronary angiography ==> Cardiac syndrome X
• Inflammation [ Time Frame: 6 months ]
  CRP > 2,98 mg/dL ==> systemic inflammation

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Bursa Yüksek İhtisas Education and Research Hospital

Dates:
Date Received: March 17, 2014
Date Started: March 2012
Date Completion:
Last Updated: March 24, 2014
Last Verified: March 2014